Treatment with inebilizumab was effective in reducing two telltale signs of an attack of neuromyelitis optica spectrum disorder, Bruce A. Cree, MD, PhD, MAS, said in this Healio video.
Cree and colleagues sought to evaluate the relationship between peripheral blood B-cell subsets andaquaporin-4 (AQP4) immunoglobulin G (IgG) titers and neuromyelitis optica spectrum disorder (NMOSD) attacks for individuals within the N-Momentum trial.
For individuals who had a clinical attack, Cree noted, there was an increase from baseline by a little over twofold, indicating that plasma cell activity was